STMN2 and cancer: Utilizing the extensive clinical data from the IMmotion150, IMmotion151, Mariathasan, Braun, and Riaz cohorts, we generated ROC curves to evaluate pan-cancer STMN2.SIG’s predictive performance in conjunction with PD-L1 expression and TMB, which consistently outperformed both PD-L1 and TMB across multiple cohorts (Figure 9F; Supplementary Figure S7D).